Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C17H25N5O4.3H2O |
| Molecular Weight | 780.8688 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N2C=NC3=C2N=CN=C3NC4CCCCC4.CO[C@@H]5[C@H](O)[C@@H](CO)O[C@H]5N6C=NC7=C6N=CN=C7NC8CCCCC8
InChI
InChIKey=PQNUNCWWHZHWNC-XLZUVWGRSA-N
InChI=1S/2C17H25N5O4.3H2O/c2*1-25-14-13(24)11(7-23)26-17(14)22-9-20-12-15(18-8-19-16(12)22)21-10-5-3-2-4-6-10;;;/h2*8-11,13-14,17,23-24H,2-7H2,1H3,(H,18,19,21);3*1H2/t2*11-,13-,14-,17-;;;/m11.../s1
| Molecular Formula | C17H25N5O4 |
| Molecular Weight | 363.4115 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9825367 | https://www.ncbi.nlm.nih.gov/pubmed/8822971 | https://www.ncbi.nlm.nih.gov/pubmed/10383546
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9825367 | https://www.ncbi.nlm.nih.gov/pubmed/8822971 | https://www.ncbi.nlm.nih.gov/pubmed/10383546
SDZ-WAG-994 is a potent and selective A1 receptor agonist, discovered by Sandoz. SDZ-WAG-994 was able to induce a dose-related and sustained fall in blood pressure and heart rate in spontaneously hypertensive rats. The compound was investigated in patients with heart failure symptoms and moderate left ventricular systolic dysfunction, where it produced no effect. In patients with patients with permanent atrial fibrillation, SDZ-WAG-994 was able to limit the increase in mean heart rate during exercise. The compound was also tested for treatment of postoperative dental pain, but for all efficacy measures, SDZ-WAG-994 was not significantly different from placebo.
Originator
Approval Year
Sample Use Guides
In a multicenter, double-blind, randomized, placebo-controlled, parallel group study, patients with permanent atrial fibrillation received 2 mg SDZWAG994 orally.
Route of Administration:
Oral
In vitro efficacy of SDZ-WAG-994 was measured by its ability to stimulate adenylate cyclase activity in rat adipocyte membranes. adipocytes from rat epididymal fat pads were homogenized, and adenylate cyclase activity was measured by the formation of [32P]cAMP from [32P]ATP. pEC50 for SDZ-WAG-994 was 6.4.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:31:27 GMT 2023
by
admin
on
Fri Dec 15 15:31:27 GMT 2023
|
| Record UNII |
0LL796AO8Y
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
71351377
Created by
admin on Fri Dec 15 15:31:27 GMT 2023 , Edited by admin on Fri Dec 15 15:31:27 GMT 2023
|
PRIMARY | |||
|
143480-90-4
Created by
admin on Fri Dec 15 15:31:27 GMT 2023 , Edited by admin on Fri Dec 15 15:31:27 GMT 2023
|
PRIMARY | |||
|
0LL796AO8Y
Created by
admin on Fri Dec 15 15:31:27 GMT 2023 , Edited by admin on Fri Dec 15 15:31:27 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ANHYDROUS->SOLVATE |
